TY - JOUR T1 - Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. JO - Eur J Health Econ PY - 2011/06/24 AU - Delea TE AU - Tappenden P AU - Sofrygin O AU - Browning D AU - Amonkar MM AU - Karnon J AU - Walker MD AU - Cameron D ED - DO - DOI: 10.1007/s10198-011-0323-1 VL - 13 IS - 5 SP - 589 EP - 603 Y2 - 2025/08/11 ER -